Strategies in conjugating geldanamycin derivatives to monoclonal antibodies that enhance Herceptin efficacy in mice bearing her2-overexpressing xenografts.

被引：0
|
作者：
Mandler, R
Kobayashi, H
Hinson, ER
Davis, MY
Sausville, EA
Newman, DJ
Yang, DJ
Roettinger, AJ
Brechbiel, MW
Waldmann, TA
机构：
[1] NCI, CCR, Metab Branch, Bethesda, MD 20892 USA
[2] NCI, Dev Therapeut Program, Bethesda, MD 20892 USA
[3] NCI, Nat Prod Branch, Bethesda, MD 20892 USA
[4] Georgetown Univ, Lombardi Canc Ctr, Washington, DC 20057 USA
[5] NCI, CCR, Radioimmune & Inorgan Chem, Bethesda, MD 20892 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2002年 / 224卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
064-BIOT
引用
收藏
页码：U209 / U209
页数：1
相关论文
共 22 条
  • [1] Herceptin:geldanamycin immunoconjugates augment the efficacy of Herceptin in mice bearing HER2-overexpressing xenografts.
    Mandler, R
    Hinson, ER
    Davis, MY
    Sausville, EA
    Newman, DJ
    Yang, D
    Roettinger, AJ
    Brechbiel, MW
    Waldmann, TA
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3786S - 3786S
  • [2] Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer
    Shak, S
    SEMINARS IN ONCOLOGY, 1999, 26 (04) : 71 - 77
  • [3] BISPECIFIC HER2 X CD3 ANTIBODIES ENHANCE T-CELL CYTOTOXICITY IN-VITRO AND LOCALIZE TO HER2-OVEREXPRESSING XENOGRAFTS IN NUDE-MICE
    SHALABY, MR
    CARTER, P
    MANEVAL, D
    GILTINAN, D
    KOTTS, C
    CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1995, 74 (02): : 185 - 192
  • [4] Potent preclinical efficacy of Herceptin-DM1 against HER2-overexpressing breast tumors in vivo.
    Schwall, RH
    Dugger, D
    Erickson, SL
    Yee, S
    Phillips, G
    Chari, RV
    Sliwkowski, MX
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3784S - 3785S
  • [5] In vitro assessment of the effects of anti-HER2 monoclonal antibodies on proliferation of HER2-overexpressing breast cancer cells
    Tahmasebi, Fathollah
    Kazemi, Tohid
    Amiri, Mohammad Mehdi
    Khoshnoodi, Jalal
    Mahmoudian, Jafar
    Bayat, Ali Ahmad
    Jeddi-Tehrani, Mahmood
    Rabbani, Hodjatallah
    Shokri, Fazel
    IMMUNOTHERAPY, 2014, 6 (01) : 43 - 49
  • [6] The pharmacokinetics, normal tissue toxicity and anti-tumor effects of [111]In-NLS-trastuzumab in mice bearing HER2-overexpressing breast cancer xenografts
    Costantini, Danny
    McLarty, Kristin
    Lee, Helen
    Done, Susan
    Vallis, Katherine
    Reilly, Raymond
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50
  • [7] Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis
    Ben-Kasus, Tsipi
    Schechter, Bilha
    Lavi, Sara
    Yarden, Yosef
    Sela, Michael
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (09) : 3294 - 3299
  • [8] Bispecific antibodies (anti-mPEG/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumors
    Su, Chia-Yu
    Chen, Michael
    Chen, Ling-Chun
    Ho, Yuan-Soon
    Ho, Hsiu-O
    Lin, Shyr-Yi
    Chuang, Kuo-Hsiang
    Sheu, Ming-Thau
    DRUG DELIVERY, 2018, 25 (01) : 1066 - 1079
  • [9] The pharmacokinetics, normal tissue toxicity and anti-tumor effects of 111In-NLS-trastuzumab in mice bearing HER2-overexpressing breast cancer xenografst
    Costantini, Danny
    McLarty, Kristin
    Lee, Helen
    Done, Susan
    Vallis, Katherine
    Reilly, Raymond
    CANCER RESEARCH, 2009, 69
  • [10] Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts
    Kristin McLarty
    Bart Cornelissen
    Deborah A. Scollard
    Susan J. Done
    Kathy Chun
    Raymond M. Reilly
    European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36 : 81 - 93
123